80 related articles for article (PubMed ID: 2821758)
1. Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans.
Gresele P; Arnout J; Deckmyn H; Vermylen J
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():248-53. PubMed ID: 2821758
[No Abstract] [Full Text] [Related]
2. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
3. [The role of prostaglandins in platelet aggregation in metabolic syndrome].
Sokolov EI; Lavrenova NIu; Goloborodova IV
Vestn Ross Akad Med Nauk; 2010; (4):22-6. PubMed ID: 20540350
[TBL] [Abstract][Full Text] [Related]
4. [Role of prostaglandins, thromboxanes and prostacyclin in regulating the thrombocyte aggregation process and liberation reaction normally and in pathology].
Baluda VP; Sushkevich GN; Lukoianova TI
Patol Fiziol Eksp Ter; 1980; (4):80-5. PubMed ID: 6251418
[No Abstract] [Full Text] [Related]
5. The effects of methyl mercury on platelets: induction of aggregation and release via activation of the prostaglandin synthesis pathway.
Macfarlane DE
Mol Pharmacol; 1981 May; 19(3):470-6. PubMed ID: 7266471
[No Abstract] [Full Text] [Related]
6. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin.
Siegl AM; Daly JW; Smith JB
Mol Pharmacol; 1982 May; 21(3):680-7. PubMed ID: 6287202
[No Abstract] [Full Text] [Related]
7. Characteristics of the aggregation of platelets and the formation of prostaglandins (PGs) in rat.
Hwang DH
Prog Lipid Res; 1981; 20():543-7. PubMed ID: 7342108
[No Abstract] [Full Text] [Related]
8. Prostacyclin analogs: antiaggregatory potency and enhancement of cAMP levels in human platelet rich plasma.
Dembinska-Kiec A; Rücker W; Schönhöfer PS; Gandolfi C
Thromb Haemost; 1979 Dec; 42(4):1340-3. PubMed ID: 232318
[No Abstract] [Full Text] [Related]
9. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
10. Effects of benoxaprofen and indomethacin on platelet function and biochemistry.
Bang NU; Dwyer AM; Marks CA; Mattler LE; Heidenreich RO; Campbell SS; Ridolfo AS
J Rheumatol Suppl; 1980; 6():27-35. PubMed ID: 6248641
[TBL] [Abstract][Full Text] [Related]
11. [Cyclic 3'-5'-AMP and prostaglandin-endoperoxide in thrombocytes of patients with circulatory insufficiency and shock].
Matthias FR; Schöndorf T
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1158-61. PubMed ID: 206043
[No Abstract] [Full Text] [Related]
12. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981.
Vane JR
J Endocrinol; 1982 Nov; 95(2):3P-43P. PubMed ID: 6816886
[No Abstract] [Full Text] [Related]
13. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
[No Abstract] [Full Text] [Related]
14. Contribution of arachidonic acid metabolites to atherosclerosis.
Dembińska-Kieć A; Gryglewski RJ
Wien Klin Wochenschr; 1986 Apr; 98(7):198-206. PubMed ID: 3010578
[TBL] [Abstract][Full Text] [Related]
15. Partial agonism of prostaglandin H2 analogs and 11-deoxy-prostaglandin F2 alpha to thromboxane-sensitive preparations.
Jones RL; Wilson NH
Adv Prostaglandin Thromboxane Res; 1980; 6():467-75. PubMed ID: 7386280
[No Abstract] [Full Text] [Related]
16. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.
Mellion BT; Ignarro LJ; Myers CB; Ohlstein EH; Ballot BA; Hyman AL; Kadowitz PJ
Mol Pharmacol; 1983 May; 23(3):653-64. PubMed ID: 6135148
[TBL] [Abstract][Full Text] [Related]
17. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
18. Prostacyclin in physiology and pathophysiology.
Vane JR; Bunting S; Moncada S
Int Rev Exp Pathol; 1982; 23():161-207. PubMed ID: 6806207
[No Abstract] [Full Text] [Related]
19. Novel prostaglandin endoperoxide analogs having prostacyclin-like actions on platelets from human and horse but not from rat and rabbit.
Wilson NH; Armstrong RA; Jones RL
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():491-5. PubMed ID: 2821762
[No Abstract] [Full Text] [Related]
20. [Hemostatic properties of thrombocytes and their cyclic 3,5-adenosine monophosphate and prostaglandin E2 content during the storage of preserved blood at 4 degrees C].
Sushkevich GN; Chebotarevskaia LV; Siatkovskiĭ VA
Probl Gematol Pereliv Krovi; 1982 Jun; 27(6):21-3. PubMed ID: 6287450
[No Abstract] [Full Text] [Related]
[Next] [New Search]
